

Supplementary Table 1. Baseline demographics and disease characteristics at week 0 of COAST-Y and disease characteristics at week 24 of COAST-Y.

	Randomised withdrawal-retreatment period (N=155)			
	Withdrawn to placebo N=53	IXE Q4W N=48	IXE Q2W N=54	Combined IXE N=102
Baseline demographics at week 0 of COAST-Y				
Age	38.5 (12.7)	36.5 (9.7)	38.4 (10.8)	37.5 (11.3)
Sex				
Male, n (%)	38 (71.7)	38 (79.2)	40 (74.1)	78 (76.5)
BMI (kg/m ²)	25.5 (3.9)	25.9 (4.5)	25.9 (4.7)	25.9 (4.6)
axSpA symptom duration (years)	12.6 (9.6)	12.6 (7.5)	12.9 (8.6)	12.7 (8.0)
axSpA diagnosis duration (years)	6.6 (7.5)	7.1 (7.0)	7.6 (8.4)	7.4 (7.7)
HLA-B27 positive, n (%) ^a	45 (84.9)	43 (89.6)	49 (90.7)	92 (90.2)
DMARDs use, n (%)	21 (39.6)	18 (37.5)	24 (44.4)	42 (41.2)
NSAID use, n (%)	50 (94.3)	44 (91.7)	51 (94.4)	95 (93.1)
Prior TNFi use, n (%) [*]				
0	44 (83.0)	39 (81.3)	46 (85.2)	85 (83.3)
1	9 (17.0)	3 (6.3)	8 (14.8)	11 (10.8)
2	0	6 (12.5)	0	6 (5.9)
Disease characteristics at week 0 of COAST-Y				
C-reactive protein (mg/L) ^a				
≤5 mg/L, n (%)	24 (45.3)	19 (39.6)	18 (33.3)	37 (36.3)
>5 mg/L, n (%)	29 (54.7)	29 (60.4)	36 (66.7)	65 (63.7)
ASDAS	1.3 (0.5)	1.3 (0.6)	1.3 (0.5)	1.3 (0.5)
ASDAS LDA (<2.1), n (%)	48 (90.6)	43 (91.5)	50 (96.2)	93 (93.9)
ASDAS ID (<1.3), n (%)	36 (67.9)	29 (61.7)	30 (57.7)	59 (59.6)
BASDAI score	1.3 (1.1)	1.4 (1.1)	1.6 (1.2)	1.5 (1.1)
BASDAI spinal pain [‡]	1.5 (1.2)	1.7 (1.5)	1.7 (1.3)	1.7 (1.4)
BASDAI morning stiffness [§]	1.1 (1.1)	1.1 (1.1)	1.3 (1.3)	1.2 (1.2)
Disease characteristics at week 24 of COAST-Y				
C-reactive protein (mg/L)				
≤5 mg/L, n (%)	46 (86.8)	38 (79.2)	49 (90.7)	87 (85.3)
>5 mg/L, n (%)	7 (13.2)	10 (20.8)	5 (9.3)	15 (14.7)
ASDAS	1.2 (0.5)	1.3 (0.5)	1.2 (0.4)	1.2 (0.5)
BASDAI score	1.2 (1.1)	1.2 (1.0)	1.3 (1.1)	1.2 (1.0)
BASDAI spinal pain [‡]	1.5 (1.7)	1.4 (1.5)	1.4 (1.2)	1.4 (1.4)
BASDAI morning stiffness [§]	1.1 (1.3)	0.8 (1.0)	0.9 (0.9)	0.8 (0.9)
PatGA	1.3 (1.4)	1.5 (1.4)	1.3 (1.2)	1.4 (1.3)
BASFI score	1.1 (1.1)	1.2 (1.2)	1.0 (1.1)	1.1 (1.2)
BASMI score	2.5 (1.3)	2.7 (1.3)	2.8 (1.4)	2.8 (1.3)

Data are presented as mean (SD), unless otherwise specified. ^aHLA-B27 status and C-reactive protein status were assessed at the start of the originating study. ^{*}Excludes adalimumab taken as study drug in COAST-V. [‡]BASDAI Question 2. [§]Mean of BASDAI Questions 5 and 6.

Abbreviations: ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; BMI, body mass index; csDMARD, conventional synthetic disease-modifying antirheumatic drug; ID, inactive disease; IXE, ixekizumab; LDA, low disease activity; N, number of patients; NSAID, non-steroidal anti-inflammatory drug; PatGA, Patient Global Assessment of Disease Activity; Q2W, every 2 weeks; Q4W, every 4 weeks; SD, standard deviation; TNFi, tumour necrosis factor inhibitor.